This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study
by Zacks Equity Research
Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.
Amgen (AMGN) Up 6.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA
by Zacks Equity Research
Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.
Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer
by Zacks Equity Research
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug
by Zacks Equity Research
Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor
by Zacks Equity Research
BridgeBio (BBIO) forms an exclusive partnership with Bristol Myers (BMY) to develop and commercialize its SHP2 inhibitor.
The Zacks Analyst Blog Highlights Amgen, Altria Group, Uber Technologies, Microchip Technology, and Arista Networks
by Zacks Equity Research
Amgen, Altria Group, Uber Technologies, Microchip Technology, and Arista Networks are part of Zacks top Analyst Blog.
Top Research Reports for Amgen, Altria Group & Uber
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Altria Group, Inc. (MO), and Uber Technologies, Inc. (UBER).
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
How Are Biotech ETFs Reacting to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Radius (RDUS) Q1 Loss Wider Than Expected, Revenues Decline
by Zacks Equity Research
Radius (RDUS) posts a y/y wider Q1 loss and misses revenue estimates.
Ligand (LGND) Q1 Earnings Beat, OmniAb Spin-Off on Track
by Zacks Equity Research
Ligand (LGND) reports encouraging first-quarter 2022 numbers by beating estimates on both counts. However, Captisol sales get hurt by lower demand for COVID-19 therapies.
Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News
by Zacks Equity Research
Earnings and regulatory updates from Bristol Myers (BMY), among others, and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Pfizer (PFE) Q1 Earnings & Sales Miss Estimates, Stock Down
by Zacks Equity Research
Pfizer (PFE) misses estimates for Q1 earnings and sales. It did not raise its sales guidance for 2022. Stock declines.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica
by Zacks Equity Research
AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares decline.
Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute
by Zacks Equity Research
Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.
Amgen (AMGN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 0.71% and 2.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More
by Kanishka Das
Let us take a look at four drug/biotech companies, namely, GSK, AMGN, ALKS and BMRN, which are due to release their quarterly results on Apr 27.
Healthcare ETFs in Focus Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.